INVENTIVA
FREURINVENTIVA (PA:IVA) — Biotechnology. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 3. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- inventivapharma.com
- Sektor
- Healthcare · Biotechnology
- Hauptsitz
- Daix, France
- CEO
- Andrew Obenshain
- Mitarbeiter
- 87
- Ausstehende Aktien
- 236.22 Mio.
- Streubesitz
- 165.57 Mio.
- Marktkapitalisierung
- 711.02 Mio. EUR
- Insider
- 12.63%
- Institutionelle Anleger
- 50.05%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- K65D
- ISIN
- FR0013233012
- LEI
- 969500I9Y690B3FZW590
Beschreibung
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Caligan Partners, LP | 3.91% | 8.16 Mio. | 2026-06-30 |
| Samsara BioCapital, LLC | 3.02% | 6.31 Mio. | 2026-06-30 |
| Paradigm Biocapital Advi… | 1.91% | 4 Mio. | 2026-06-30 |
| Andera Partners | 1.74% | 3.63 Mio. | 2026-06-30 |
| Adar1 Capital Management… | 1.73% | 3.61 Mio. | 2026-06-30 |
| Millennium Management Ll… | 1.68% | 3.51 Mio. | 2026-06-30 |
| Nantahala Capital Manage… | 1.29% | 2.69 Mio. | 2026-06-30 |
| Trails Edge Capital Part… | 1.27% | 2.66 Mio. | 2026-06-30 |
| Franklin Resources, Inc. | 1.26% | 2.64 Mio. | 2026-06-30 |
| Squadron Capital Managem… | 1.17% | 2.44 Mio. | 2026-06-30 |
| abrdn World Healthcare F… | 0.58% | 1.21 Mio. | 2026-06-30 |
| abrdn Life Sciences Inve… | 0.52% | 1.09 Mio. | 2026-06-30 |
| Franklin Strategic Serie… | 0.49% | 1.01 Mio. | 2026-07-31 |
| Fidelity Advisor Series… | 0.33% | 685 400 | 2026-07-31 |
| Artisan Partners Funds I… | 0.27% | 637 859 | 2026-06-30 |
| Simplify Exchange Traded… | 0.15% | 313 483 | 2026-06-30 |
| Fidelity Concord Street… | 0.07% | 154 400 | 2026-07-31 |
| Fidelity Concord Street… | 0.07% | 136 161 | 2026-07-31 |
| Fidelity Rutland Square… | 0.03% | 63 678 | 2026-07-31 |
| Blackstone Alternative I… | 0.02% | 42 752 | 2026-06-30 |
| Fidelity Concord Street… | 0.01% | 29 300 | 2026-07-31 |
| -SSgA SPDR ETFS Europe I… | 0.01% | 16 409 | 2026-07-31 |
| -SSgA SPDR ETFS Europe I… | 0% | 9 843 | 2026-07-31 |
| -SSgA SPDR ETFS Europe I… | 0% | 3 704 | 2026-07-31 |
| DBX ETF Trust-Xtrackers… | 0% | 1 327 | 2026-05-31 |
| -Goldman Sachs MSCI Worl… | 0% | 301 | 2026-08-31 |
